In the article "Birth Outcomes Following Zidovudine Therapy in
Pregnant Women," on page 415 the second sentence of the first full
paragraph should read "In January 1993, the Zidovudine in Pregnancy
Registry was expanded to include zalcitabine and became the
Antiretroviral Pregnancy Registry jointly managed by Burroughs
Wellcome Co. and Hoffmann-LaRoche Inc."
Any pregnancies exposed to either zidovudine or zalcitabine
should be reported to the registry, telephone (800) 722-9292,
extension 8465, within the United States and (919) 315-8465 for
registrations from outside the United States.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the electronic PDF version and/or the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
